REC-2282

Small molecule

RRecursion Pharmaceuticals Inc.

REC-2282 is one of 20 small molecule programs targeting Neurofibromatosis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeurofibromatosisActive, not recruiting

NeurofibromatosisPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

25 competitors in Neurofibromatosis

#DrugCompanyPhaseTrials

Rapamune

PPrism Pharmaceuticals

Approved

—2

Oncovin

EEastern Cooperative Oncology Group

Paraplatin

Koselugo

3 5

Tykerb

GSK

Phase 2

1 6

Gleevec

Novartis

Phase 2

1 7

Afinitor

Novartis

Phase 2

1 8

Verzenio

Eli Lilly

Phase 2

—9

Selumetinib /m2

NNational Cancer Institute (NCI)

Phase 3

—10

Conmana

BBetta Pharmaceuticals Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neurofibromatosis1 trial

Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

Terminated·RRecursion Pharmaceuticals Inc.·Phase 2/3·NCT05130866·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for REC-2282. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REC-2282 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REC-2282. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Recursion Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: RRecursion Pharmaceuticals Inc.

REC-2282

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neurofibromatosis1 trial

References

Drug Info

Quick Facts

Related News